EGFR and neoplasm: In the present study, among 46 patients with NSCLC receiving EGFR-TKIs, 12 patients had PR, 21 patients had SD, and 13 patients had PD; hence, the tumor response rate (CR+PR) was 26.09%, which was similar to the response rates of Japanese patients in IDEAL 1.